Login / Signup

Addition of Lenalidomide to R-CHOP Improves Outcomes in Newly Diagnosed Diffuse Large B-Cell Lymphoma in a Randomized Phase II US Intergroup Study ECOG-ACRIN E1412.

Grzegorz S NowakowskiFangxin HongDavid W ScottWilliam R MaconRebecca L KingThomas M HabermannNina Wagner-JohnstonCarla CasuloJames L WadeGauri G NagargojeC M ReynoldsJonathon B CohenNadia KhanJennifer Effie AmengualKristy L RichardsRichard F LittleJohn P LeonardJonathan W FriedbergLale KostakogluBrad S KahlThomas E Witzig
Published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021)
In this signal-seeking study, the addition of lenalidomide to R-CHOP (R2CHOP) improved outcomes in newly diagnosed DLBCL including patients with ABC-DLBCL.
Keyphrases
  • diffuse large b cell lymphoma
  • newly diagnosed
  • epstein barr virus
  • phase ii
  • clinical trial
  • multiple myeloma
  • mental health
  • low dose
  • stem cell transplantation
  • placebo controlled